Novo Nordisk CEO Open to Direct NYSE Listing to Boost U.S. Profile

Novo Nordisk is open to the possibility of upgrading its U.S. stock market presence with a direct listing on the New York Stock Exchange, according to comments from its CEO. In an interview with the Financial Times published Wednesday, CEO Mike Doustdar said he sees advantages in such a move, which would aim to boost the company's profile among American investors.

Details of the Potential Move

A direct listing would replace the American depositary receipts (ADRs) that currently provide U.S. investors with access to the Danish pharmaceutical giant. While acknowledging the benefits, Doustdar specified that Novo Nordisk is not currently exploring the idea. The potential shift would follow a similar decision made by UK-based drugmaker AstraZeneca earlier this year.

Novo Nordisk, Denmark's largest company by market value, maintains its primary listing on the Nasdaq Copenhagen exchange.

Ad

Strategic Importance of the U.S.

The consideration reflects the growing significance of the American market for the company's business and investor base. Key details include:

• The U.S. market now represents more than half of Novo Nordisk's total revenue.
• A significant portion of these sales comes from its popular diabetes and weight-loss medications, including Ozempic.
• The company has seen a corresponding increase in the number of its investors based in the United States, making the market strategically crucial for corporate visibility and capital access.